Our lab focuses on developing cell-based and gene-based therapies for neurodegenerative diseases. We use advanced methods, such as CRISPR/Cas9 for in vivo gene modification, and take advantage of multiple platforms for the delivery of therapeutics into the CNS, including mesenchymal stem cells, exosomes and peptides. Using cell cultures and animal models, we evaluate the effect of gene modification on cognition and behaviour, as well as on disease-related biochemical and histological features.
News and Media
May 2021, Roy Rabinowitz is awarded the Dan David Prize Scholarship in Molecular Medicine
2021 העולם היום | החומר הפעיל בקנביס תורם לטיפול בילדים הלוקים באוטיזם- ראיון עם שני פולג, אפריל
28.2.18 New publication now available on pubmed - "DJ-1 based peptide, ND-13, promote functional recovery in mouse model of focal ischemic injury"
12.11.17 New publication now available on pubmed - "Implantation of 3D Constructs Embedded with Oral Mucosa-Derived Cells Induces Functional Recovery in Rats with Complete Spinal Cord Transection"